The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases

[1]  T. Treasure,et al.  Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial , 2017 .

[2]  R. Klement.  Radiobiological parameters of liver and lung metastases derived from tumor control data of 3719 metastases. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  R. Semrau,et al.  Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  M. Eble,et al.  Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  J. Lee,et al.  Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study , 2016, The Lancet. Oncology.

[6]  Henry Knipe,et al.  Oligometastases , 2016, Radiopaedia.org.

[7]  S. Eschrich,et al.  Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. , 2016, International journal of radiation oncology, biology, physics.

[8]  L. Uhlmann,et al.  Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy". , 2016, Lung cancer.

[9]  D. Rades,et al.  Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases , 2016, Radiation oncology.

[10]  Kyu Ha Lee,et al.  Semi-Competing Risks Data Analysis: Accounting for Death as a Competing Risk When the Outcome of Interest Is Nonterminal , 2016, Circulation. Cardiovascular quality and outcomes.

[11]  M. Duma,et al.  Bayesian Cure Rate Modeling of Local Tumor Control: Evaluation in Stereotactic Body Radiation Therapy for Pulmonary Metastases. , 2016, International Journal of Radiation Oncology, Biology, Physics.

[12]  Ahmedin Jemal,et al.  Global patterns and trends in colorectal cancer incidence and mortality , 2016, Gut.

[13]  SebastienHaneuse,et al.  Semi-Competing Risks Data Analysis , 2016 .

[14]  Virginie Rondeau,et al.  A joint model for the dependence between clustered times to tumour progression and deaths: A meta-analysis of chemotherapy in head and neck cancer , 2015, Statistical methods in medical research.

[15]  S. Eschrich,et al.  Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection. , 2014, International journal of radiation oncology, biology, physics.

[16]  I. Poon,et al.  Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

[17]  A. Viste,et al.  Surgery for colorectal liver metastases: the impact of resection margins on recurrence and overall survival , 2014, World Journal of Surgical Oncology.

[18]  Deepinder P. Singh,et al.  Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. , 2014, Journal of thoracic disease.

[19]  J. Shindoh,et al.  Adjuvant Chemotherapy With FOLFOX for Primary Colorectal Cancer Is Associated With Increased Somatic Gene Mutations and Inferior Survival in Patients Undergoing Hepatectomy for Metachronous Liver Metastases , 2012, Annals of surgery.

[20]  P. Okunieff,et al.  Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. , 2012, International journal of radiation oncology, biology, physics.

[21]  R. Weichselbaum,et al.  Stereotactic body radiotherapy for multisite extracranial oligometastases , 2012, Cancer.

[22]  Virginie Rondeau,et al.  frailtypack: An R Package for the Analysis of Correlated Survival Data with Frailty Models Using Penalized Likelihood Estimation or Parametrical Estimation , 2012 .

[23]  Stef van Buuren,et al.  MICE: Multivariate Imputation by Chained Equations in R , 2011 .

[24]  E. Kunieda,et al.  Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  F. Petrella,et al.  A 10-Year Single-Center Experience on 708 Lung Metastasectomies: The Evidence of the “International Registry of Lung Metastases” , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  E. Steyerberg,et al.  [Regression modeling strategies]. , 2011, Revista espanola de cardiologia.

[27]  Jinfeng Xu,et al.  Statistical Analysis of Illness–Death Processes and Semicompeting Risks Data , 2010, Biometrics.

[28]  V. Heinemann,et al.  Radiosurgery of Liver Tumors: Value of Robotic Radiosurgical Device to Treat Liver Tumors , 2010, Annals of Surgical Oncology.

[29]  L. Gaspar,et al.  Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  W. Franklin,et al.  Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Weichselbaum,et al.  A rationale for the targeted treatment of oligometastases with radiotherapy , 2008, Journal of surgical oncology.

[32]  A. Gelman.  Scaling regression inputs by dividing by two standard deviations , 2008, Statistics in medicine.

[33]  Paul Janssen,et al.  Frailty Model , 2007, International Encyclopedia of Statistical Science.

[34]  Jon Williamson,et al.  Interpreting Causality in the Health Sciences , 2007 .

[35]  M. Schell,et al.  Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. , 2007, International journal of radiation oncology, biology, physics.

[36]  U. Haedinger,et al.  Stereotactic radiotherapy of primary liver cancer and hepatic metastases , 2006, Acta oncologica.

[37]  Abraham Philip,et al.  Stereotactic Body Radiation Therapy (SBRT) for lung metastases , 2006, Acta oncologica.

[38]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[39]  L H Blumgart,et al.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. , 1999, Annals of surgery.

[40]  O. Salazar.  Colorectal Cancer: Metastatic Patterns and Prognosis , 1993, Southern medical journal.